Macrolide resistance due to <i>erm</i> (55)
Macrolide antibiotics are often the only oral treatment option for infections with rapidly growing mycobacteria such as <i>Mycobacterium abscessus</i> and <i>Mycobacterium chelonae</i>. We previously identified three variants of a newly predicted macrolide resistance gene, <i>erm</i>(55), in <i>M. chelonae</i>, including the first case of a plasmid-mediated macrolide resistance in mycobacteria. The present study provides experimental evidence that the three <i>erm</i>(55) variants confer macrolide resistance and that each variant is unique in the degree to which it reduces susceptibility to clinically relevant macrolides.
Authors
- Barbara A. Brown‐Elliott (ORCID: https://orcid.org/0000-0002-3091-1169)
- Danae M. Suchan (ORCID: https://orcid.org/0000-0001-8961-652X)
- Sean D. Workman (ORCID: https://orcid.org/0000-0001-8807-4466)
- Omar M. El-Halfawy (ORCID: https://orcid.org/0000-0003-2829-5851)
- Andrew D. S. Cameron (ORCID: https://orcid.org/0000-0003-1560-8572)
- David C. Alexander (ORCID: https://orcid.org/0000-0003-3509-445X)
- Richard J. Wallace (ORCID: https://orcid.org/0000-0002-4120-0143)
- Joshua M. E. Adams
- Tayah Farquhar
Institutions
- Manitoba Health (CA)
- University of Regina (CA)
- The University of Texas at Tyler (US)
- University of Manitoba (CA)
- Alexandria University (EG)
- The University of Texas Health Science Center at Tyler (US)
Publication Details
- Journal
- Microbiology Spectrum
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1128/spectrum.02397-24
- Citations
- 4
- Primary Topic
- Mycobacterium research and diagnosis
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- Saskatchewan Health Research Foundation
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada